Logo

Takeda Recalls Natpara (parathyroid hormone) Injection Formulation in the US

Share this

Takeda Recalls Natpara (parathyroid hormone) Injection Formulation in the US

Shots:

  • Takeda is issuing a recall for all doses of Natpara for injection (25/50/75/100 mcg) in the US after the discussion with US FDA due to the potential for rubber particulate instigating from the rubber septum of the NATPARA cartridge
  • Takeda is advising patients to consult with their healthcare providers about the discontinuation of Natpara treatment as it may lead to severe hypocalcemia resulting in serious health consequences
  • Natpara is a recombinant human protein with 84 amino acid sequence of endogenous parathyroid hormone. Healthcare providers can contact Takeda for queries related to recall at +1-800-828-2088 & select Option 2 and patients can contact OnePath at +1-866-888-0660

Click here to­ read full press release/ article

Ref: Takeda | Image: Takeda


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions